Noboru Yamamoto

Research interests

Publications

• First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

  Journal of Clinical Oncology · 2023 · 10.1200/jco.23.00059

• Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

  Clinical Cancer Research · 2021 · 10.1158/1078-0432.ccr-20-4405

• A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

  European Journal of Cancer · 2020 · 10.1016/j.ejca.2020.02.016

• Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30162-5

• A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

  Clinical Cancer Research · 2019 · 10.1158/1078-0432.ccr-19-1090

• Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30678-3

• Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30678-3

• Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

  Cancer Science · 2019 · https://doi.org/10.1111/cas.13969

• Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.75.5587

• Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

  Cancer Science · 2018 · 10.1111/cas.13800

• Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

  The Lancet Respiratory Medicine · 2016 · 10.1016/s2213-2600(16)30322-8

• Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

  Oncotarget · 2016 · 10.18632/oncotarget.12677

• Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70381-x

• Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70381-x

• Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-2638

• Development of a new pH-swing CO2 mineralization process with a recyclable reaction solution

  Energy · 2008 · 10.1016/j.energy.2008.01.005

• EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.16.7254

• Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

  Pharmacogenetics and Genomics · 2007 · 10.1097/fpc.0b013e328014341f

• Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.01.0793

• Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

  Lung Cancer · 2004 · 10.1016/j.lungcan.2004.01.010

• Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population

  Human Mutation · 2003 · 10.1002/humu.9210

• Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

  Annals of Oncology · 2003 · 10.1093/annonc/mdg250

• Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

  Annals of Oncology · 2003 · 10.1093/annonc/mdg250

Current projects

No projects listed.